#emcure
India Licenses SHetA2 Drug For Cervical Precancer Treatment
ICMR has licensed SHetA2 to Emcure for further development as a potential treatment for HPV-related cervical precancer, though it is not yet approved for patients. What Is SHetA2? SHetA2 is an investigational anti-HPV drug candidate being developed as a possible treatment for cervical intraepithelial neoplasia, commonly known as CIN. CIN refers to abnormal changes in the cells covering the cervix. These changes are not cancer, but high-
India Licenses SHetA2 Drug For Cervical Precancer Treatment
ICMR has licensed SHetA2 to Emcure for further development as a potential treatment for HPV-related cervical precancer, though it is not yet approved for patients. What Is SHetA2? SHetA2 is an investigational anti-HPV drug candidate being developed as a possible treatment for cervical intraepithelial neoplasia, commonly known as CIN. CIN refers to abnormal changes in the cells covering the cervix. These changes are not cancer, but high-









